Sinonasal inhalation of dornase alfa administered by vibrating aerosol to cystic fibrosis patients: A double-blind placebo-controlled cross-over trial-Reference-Cited by-同舟云学术

Sinonasal inhalation of dornase alfa administered by vibrating aerosol to cystic fibrosis patients: A double-blind placebo-controlled cross-over trial

Published:2014-07 Issue:4 Volume:13 Page:461-470
ISSN:1569-1993
Container-title:Journal of Cystic Fibrosis
language:en
Short-container-title:Journal of Cystic Fibrosis

Author:

Mainz Jochen G.,Schien Claudia,Schiller Isabella,Schädlich Katja,Koitschev Assen,Koitschev Christiane,Riethmüller Joachim,Graepler-Mainka Uta,Wiedemann Bärbel,Beck James F.

Funder

Roche Pharma Germany

Roche

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Pediatrics, Perinatology and Child Health

Reference41 articles.

1. Sinonasal disease in cystic fibrosis: clinical characteristics, diagnosis, and management;Gysin;Pediatr Pulmonol,2000

2. Cystic fibrosis upper airways primary colonization with Pseudomonas aeruginosa: eradicated by sinonasal antibiotic inhalation;Mainz;Am J Respir Crit Care Med,2011

3. Complementary role of MR imaging of ethmomaxillary sinus disease depicted at CT in cystic fibrosis;Eggesbo;Acta Radiol,2001

4. CT of the paranasal sinuses is not a valid indicator for sinus surgery in CF patients;Rasmussen;J Cyst Fibros,2010

5. Rhinosinusitis in cystic fibrosis: not a simple story;Babinski;Int J Pediatr Otorhinolaryngol,2008

Cited by 68 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Opportunities for nanomaterials in enzyme therapy;Journal of Controlled Release;2024-08

2. ECFS standards of care on CFTR-related disorders: Identification and care of the disorders;Journal of Cystic Fibrosis;2024-07

3. Pädiatrische Rhinologie;Laryngo-Rhino-Otologie;2024-05

4. Surgical and medical management of chronic rhinosinusitis in pediatric cystic fibrosis patients: Impact on olfactory symptoms;International Journal of Pediatric Otorhinolaryngology;2024-04

5. Recombinant Human Deoxyribonuclease I;Pharmaceutical Biotechnology;2024